Begona Carreno

Chief Business Development Officer at Idorsia

Speaker

Begoña Carreño-Gómez, PhD, is a biopharmaceutical business development executive with more than 25 years of experience

spanning research, strategy, and deal-making across global pharmaceutical and biotechnology companies. As of November 1^st she is the Chief Business Development Officer (CBDO) and member of the Executive Committee at Idorsia Pharmaceuticals Ltd.

She most recently served as CBDO at Aspeya Switzerland SA, where she built and led the company’s Business

Development and Licensing function and team for the last 3 years.

Prior to that, Begoña was Global Business Development & Licensing Head in the Ophthalmology franchise at Novartis

Pharma, AG, based in Basel where she spent over 19 years leading

BD&L efforts across five different therapeutic franchises (respiratory, cardiovascular, metabolism, arthritis, bone and

musculoskeletal diseases), as well as a proven track record in licensing deals and M&A. Before joining Novartis, she was the Head

of External Pharmaceutical projects at Almirall (Barcelona, Spain). She is also an independent Non executive Director & Supervisory Board member at ProQr Therapeutics since 2022; member of the Business Advisory Board at the Institute for research in Biomedicine (IRB) in Barcelona since 2013 and an advisor and member of the Scientific Advisory Board at In Vivo Capital since 2025.

Dr. Carreño holds a PhD in Drug Delivery from the London School of Pharmacy, a 3-year Postdoctoral Research fellow at the

Centre for Polymer Therapeutics (London School of Pharmacy, UK) and a BSc in Biochemistry from Keele University (UK).